Respirable rifampicin-based microspheres containing isoniazid for tuberculosis treatment
β Scribed by Roberta Cassano; Sonia Trombino; Teresa Ferrarelli; Maria Vittoria Mauro; Cristina Giraldi; Maria Manconi; Anna Maria Fadda; Nevio Picci
- Book ID
- 102875084
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 503 KB
- Volume
- 100A
- Category
- Article
- ISSN
- 1549-3296
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The purpose of this investigation was to develop small microspheres for delivering antimycobacterial drugs to infected host macrophages. Rifampicinβbased microparticles were prepared. The drug was covalently linked to acrylic moieties to obtain a polymerizable derivative for the preparation of materials useful as drug delivery systems that then were loaded with isoniazid acting in synergy with rifampicin. Their antitubercular activity was determined in vitro. Fourier transform infrared spectroscopy confirmed hydrogel structure. Morphological analysis showed microparticles with spherical shape and homogeneous surface. In vitro release studies were performed in media simulating physiologic pH (7.4) and endosomal of alveolar macrophages pH (5.2). A similar amount of isoniazid was delivered within the first 6 h at both pHs, while a smaller amount of the drug was delivered at pH 7.4 in the last phase of the study. In vitro antitubercular activity showed a behavior comparable to that of rifampicin and isoniazid free. Bioactive swelling matrices, showing a high swelling degree into a medium miming intra alveolar environment, were obtained. They could be applied for their antitubercular activity. Β© 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2012.
π SIMILAR VOLUMES
## Background: Rifapentine has a long half-life in serum, which suggests a possible treatment once a week for tuberculosis. we aimed to compare rifapentine and isoniazid once a week with rifampicin and isoniazid twice a week. ## Methods: We did a randomised, multicentre, open-label trial in the u